Sodium Hyaluronate in the Treatment of Interstitial Cystitis

DU Peng,QIAO Yong-zhong,ZHU Xu-hui,LI Tao,ZHANG Peng,YANG Yong

DOI: https://doi.org/10.3760/cma.j.issn.1000-6702.2009.09.007

2009-01-01

Abstract:adder irritation after intra-vesical sodium hyaluronate therapy. Conclusion Intravesical sodium hyaluronate therapy can effec-tively relieve clinical symptom of IC and improve IC patients' quality of life and is well tolerated.

What problem does this paper attempt to address?

Intravesical Instillation of Sodium Hyaluronate for the Treatment of Refractory Non-Bacterial Cystitis:A Multicenter Study

FAN Jie

DOI: https://doi.org/10.3760/j:issn:1000-6702.2006.07.015

2006-01-01

Abstract:Objective To evaluate the efficacy and safety of intravesical instillation of sodium hya- luronate in relieving the symptoms of refractory non-bacterial cystitis.Methods Totally,20 patients(1 man and 19 women;mean age,47 years;age range,22-68 years)with refractory non-bacterial cystitis were included.Their disease course ranged from 1 month to 30 years.Of them,16 patients had the disease for more than 1 year.Instillation of sodium hyaluronate(50 ml solution of 40 mg HA)was performed intravesically in them for a total of 12 weeks(once a week for the first 4 weeks and once every 4 weeks for the succeeding 8 weeks).Follow-up visit ended at 16 weeks,when the patients filled in the symptom assessment scores(VAS on pain,frequency and urgency)according to the subjective evaluation.Therapeutic results were classified as(1)total response:symptom disappearance or relief by at least 90% of the symptom scores;(2)partial response:symptom relief by 50%-89%;(3)mild response:symptom relief by 49% or less;(4)no re- sponse:no improvement in symptom scores.Results Nineteen patients completed the 16-week follow-up with only 1 withdrawing.The average general symptom score decreased from 22.32±5.53 to 9.47±5.88 (P＜0.001);frequency score from 8.21±1.75 to 3.89v2.31(P＜0.001);urgency score from 7.47±2.14 to 3.37±2.14(P＜0.001);pain score from 6.63±3.47 to 2.21±2.74(P＜0.001).After 16 weeks,overall positive response rate(total+partial response)was 53%(10/19).No serious adverse effect occurred except for urethral irritation(25%,5/20),worsening of distending pain of the bladder(5%,1/20) and vertigo(15%,3/20)caused by the procedure itself.Conclusions For patients suffering from refrac- tory non-bacterial cystitis,intravesical instillations of sodium hyaluronate can significantly relieve the symp- toms and is safe and of good patient compliance.
Intravesical Hyaluronic Acid Combined with Heparin in the Treatment of Refractory Interstitial Cystitis

L(U) Yi-song,ZHOU Hui-liang,MAO Hou-ping,GAO Rui,XUE Xue-yi,CAO Lin-sheng,LUO Yi-qi

DOI: https://doi.org/10.3969/j.issn.1007-6611.2012.01.016

2012-01-01

Abstract:Objective To evaluate the efficacy of intravesical instillation of hyaluronic acid(HA) and heparin for refractory interstitial cystitis(IC).Methods A total of 24 patients with IC were enrolled.They received intravesical 40 mg HA and 40 000 U heparin weekly for 8 weeks and then monthly for 4 months.Patients were followed up for 6 months after the last instillation.The voids per day,average urine volume,O'Leary-Sant interstitial cystitis symptom index and problem index(ICSI/ICPI),and pelvic pain and urgency frequency(PUF) were observed before and after treatment,and cystoscopy and potassium sensitivity test was performed before and after treatment.Results A total of 23 patients completed the treatment and the follow-up.At 3 month after follow-up,voids per day decreased significantly,average urine volume increased significantly,and ICSI,ICPI,PUF also decreased significantly(P0.01).At 6 month after follow-up,all indices were sustained and were better than those before treatment(P0.01),but there was no significant difference between month 6 and month 3(P0.05).The patients with positive potassium sensitivity test decreased from 16 to 2,and the bleeding point of mucous membrane disappeared or was alleviated in 19 patients.Conclusion The efficacy of intravesical instillation of HA and heparin is reliable for patients with refractory IC.
The efficacy and safety of amitriptyline combined with sodium hyaluronate therapy for bladder pain syndrome(Report of 58 cases)

ZHU Xuhui,DU Peng,SHAN Hui,LI Tao,ZHANG Peng,YANG Yong

DOI: https://doi.org/10.13201/j.issn.1001-1420.2012.02.006

2012-01-01

Journal of Clinical Urology

Abstract:Objective:To evaluate the efficacy and safety of the therapy treating patients with amitriptyline combined with intravesical sodium hyaluronate(CYSTISTAT;Sterile Sodium Hyaluronate Solution) for Bladder Pain Syndrome/Interstitial Cystitis(BPS/IC). Method:Fifty-eight patients with BPS/IC were involved in this six-month,prospective trial.All 58 patients received oral amitriptyline(25 mg) 2 times daily for 24 weeks each;and intravesical sodium hyaluronate therapy once a week for 4 weeks,then once a month for 5 months.Clinical symptoms(micturition frequency per day,maximal micturition volume and cystodynia degree score),O'Leary-Sant IC symptom and problem index,and quality of life score,and quantifying mast cells were assessed at baseline and then again after 1,3 and 6 months of treatment.Side effects was recorded. Result:There were 16 male and 42 female patients in our study,the average age was(50.0±11.2)(range from 24 to 65),the average duration of symptoms was(5.7±1.3) years(from 1-10 years)before treatment.The response rate was 62.1%(36/58),Overall satisfaction was 39.7%(23/58).Partial satisfaction was 22.4%(13/58).None response was 37.9%(22/58).For all patients,the mean voiding times,voiding volume,cystodynia degree score,average O'Leary Sant score,quality of life score and quantifying mast cells and pre-treatment were statistically improved post-treatment respectively,P<0.001. Conclusion:Treating BPS/IC patients with amitriptyline and intravesical sodium hyaluronate can effectively relieve clinical symptom of BPS/IC and improve BPS/IC patients' quality of life and is well tolerated.
Intravesical Hyaluronic Acid and Alkalinized Lidocaine for the Treatment of Severe Painful Bladder Syndrome/interstitial Cystitis

Yi-Song Lv,Hui-Liang Zhou,Hou-Ping Mao,Rui Gao,Yan-Dong Wang,Xue-Yi Xue

DOI: https://doi.org/10.1007/s00192-012-1802-3

2012-01-01

International Urogynecology Journal

Abstract:Introduction and hypothesis Intravesical instillation of hyaluronic acid (HA) may restore the integrity of glycosaminoglycan layer in patients with painful bladder syndrome/interstitial cystitis (PBS/IC), and the benefit may be improved with addition of alkalinized lidocaine (AL). Methods 48 women with severe PBS/IC who failed oral medications were enrolled and divided into one trial and two control groups. The trial group received intravesical 40 mg HA, 10 ml of 2 % lidocaine and 5 ml of 8.4 % sodium bicarbonate on a weekly basis for 8 weeks and then monthly for 4 months with a subsequent follow-up of 24 weeks, while the two control groups received 40 mg HA and mixture of 10 ml of 2 % lidocaine and 5 ml of 8.4%sodium bicarbonate respectively following the same procedure. Response to therapy was evaluated by Global Response Assessment, voids per day, Visual Analogue Scale for pain, frequency and urgency, O’leary-Sant Interstitial Cystitis Symptom Index and Problem Index, cystoscopy and bladder capacity. Results Overall 45 patients finished this study protocol. The HA + AL group and the AL group showed significant improvement at week 2 ( P < 0.01), while the HA group began to show effect at week 4 ( P < 0.01). There was no improvement in the AL group at week 24 and these patients quitted the study without follow up. Contrarily, the HA + AL and HA group kept on improving till the end of the study without significant difference between the two groups. Conclusions Intravesical instillation of HA and AL may provide both immediate and sustained relief of symptoms in severe PBS/IC in this preliminary study.
Intravesical Instillations of Hyaluronic Acid as First-Line Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome: Use, Efficacy and Effects on Quality of Life

Francesco Plotti,Gianna Barbara Cundari,Fernando Ficarola,Corrado Terranova,Carlo De Cicco Nardone,Roberto Montera,Daniela Luvero,Federica Guzzo,Adele Silvagni,Amerigo Ferrari,Donatella Caserta,Roberto Angioli

DOI: https://doi.org/10.3390/healthcare12121190

2024-06-14

Health Care

Abstract:The efficacy of hyaluronic acid instillations as therapy for patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) has been demonstrated in some clinical studies, with response rates up to 70%. The aim of the study is to investigate the change in symptoms and quality of life in female patients with IC/BPS after intravesical instillations of hyaluronic acid used as first-line treatment. A retrospective single-center cohort study was conducted. Female patients, whose symptoms were compatible with the diagnosis of IC/BPS as defined by the International Continence Society, were treated with a variable number of intravesical instillations of a hyaluronic acid-based drug. Three validated questionnaires were administered by telephone to all patients, before the beginning of the treatment and 6 months after the last administration of the drug. A total of 50 patients with symptoms compatible with the diagnosis of IC/BPS were included in the study. The median number of instillations performed is 4. For all questionnaires, the median value was significantly reduced following treatment with intravesical instillations (p = 0.000). The present study has shown that intravesical hyaluronic acid treatment results in both statistically and clinically significant symptomatic improvement, thereby improving the quality of life of patients with IC/BPS.

health care sciences & services,health policy & services
Efficacy assessment of bladder hydrodistension combined with drug intravesical instilla-tion for treatment of interstitial cystitis/bladder pain syndrome

Qiang CHEN,Shuyin ZHOU,Mao ZHANG,Deyun LIU

DOI: https://doi.org/10.3969/j.issn.1004-3594.2014.12.006

2014-01-01

Abstract:Objective To explore the efficacy of bladder hydrodistension combined with drug intravesical therapy in treatment of IC/BPS.Methods O’ Leary-Sant questionnaire and PUF were used to assess the patients’ symptoms.Depending on the intravesi-cal drugs, the patients were divided into groups A and B.To group A, hyaluronic acid was administered intravesically; To group B, heparin cocktail was given intravesically.The efficacy was comparied between the two groups before and after treatment.Results Af-ter 6 months of treatment, the total effective rates were 88.6%(group A) and 86.1%(B group) respectively.Comparing the total ef-fective rates of the two groups, there was no statistically significant difference (P=0.074).Compared with before treatment, the ob-served indicators in the two groups of patients were improved(P<0.05) after treatment at 1,3,6 months.1 month after treatment, the difference between the two groups was not significant (P>0.05), 3 months and 6 months after treatment, differences between the two groups were statistically significant(P<0.05).Conclusions Hydrodistension combined with intravesical instillation of hyaluronic acid or heparin cocktail method can effectively alleviate the symptoms of patients with IC/BPS; hyaluronic acid is superior to heparin cocktail method in the long-term efficacy.
Efficacy Comparison of Interstitial Cystitis/painful Bladder Syndrome Patients Treated with Four-Drug Combination and Sodium Hyaluronate Intravesical Instillation

Fang Zhiwei,Zhang Xiaopeng,Hu Hao,Xu Kexin,Huang Xiaobo,Wang Xiaofeng

DOI: https://doi.org/10.3760/cma.j.issn.1000-6702.2015.04.010

2015-01-01

Abstract:Objective To compare the outcomes between interstitial cystitis/painful bladder syndrome (IC/PBS) patients treated with four-drug combination (heparin,lidocaine,sodium bicarbonate,gentamicin) and sodium hyaluronate intravesical instillation.Methods There were 23 IC/PBS patients from Jan.1,2011 to Mar.1,2013.Ten patients (group A) received four-drug combination (heparin 40 000 U,'gentamicin 160 000 U,sodium bicarbonate 1％,lidocaine 0.4％) instillation treatment.Thirteen patients received instillation of sodium hyaluronate (40 mg/50 ml) therapy (group B).In group B,intravesical instillations were performed weekly in the first 6-8 weeks,and monthly until one year.Patients in group A received intravesical instillation twice a week in the first 6-8 weeks and twice a month for 10 months.All the patients were instructed to retain the instillation volume for at least one hour.Clinical symptoms (24 h frequency of urination,maximal micturition volume),O'Leary-Sant symptom and problem index were assessed at baseline and 1,6 and 12 months after treatment.The 2 therapies were compared within curative effects and side effects.Results Twenty-two of the 23 patients were followed up to 12 months.Patients in group A had no adverse events reported.One case of group B dropped out from treatment for recurrent urinary tract infection,and the other two cases felt painful in bladder area during instillation.There was no significant difference in initial scores between the 2 groups (P＞0.05).At 1,6,12 months after intravesical instillation,interstitial cystitis symptom index,interstitial cystitis problem index,24 h frequency of urination,the maximum bladder capacity were improved in both groups.All indicators in group A and B were improved significantly after treatment compared with pretreatment (P ＜ 0.05).≥ 25％ decrease of interstitial cystitis symptom index or ≥25％ decrease of 24 h frequency of urination were defined as remission.Remission rates of the 2 groups at each time point were:1 month after treatment (100％ versus 100％,P=1.000),6 months after treatment (80％ versus 83％,P=1.000),1 year after treatment (70％ versus 75％,P=1.000).There were no significant differences between the 2 groups in all time points for the outcomes (P ＞ 0.05).Conclusion The four-drug combination intravesical instillation could achieve a similar effect with hyaluronic acid therapy in patients with IC/PBS.
Intravesical Interferon Therapy for Pain Among Female Individuals With Interstitial Cystitis

Si-hong Shen,Liao Peng,Xiao Zeng,Jie Zhang,Hong Shen,De-yi Luo

DOI: https://doi.org/10.1001/jamanetworkopen.2024.4880

2024-04-09

JAMA Network Open

Abstract:This randomized clinical trial examines the safety and efficacy of intravesical interferon instillation compared with hyaluronic acid in female patients with interstitial cystitis.

medicine, general & internal
[The Study of Diagnosis and Treatment of Interstitial Cystitis].

Zhong-quan Sun,Wei-qing Qian,Dan-sheng Xie,Jian-da Song

DOI: https://doi.org/10.3760/j:issn:0529-5815.2005.10.016

2005-01-01

Abstract:OBJECTIVE:To discuss the diagnosis and treatment interstitial cystitis (IC).METHODS:The clinical date of 10 cases of IC (all women) were analyzed. Their age ranged from 31 to 63 years, with a mean of 41 years. Their courses ranged from 1.5 to 7 years, with a mean of 3.4 years. The symptom criteria of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) was met for IC and no patients had Hunner's ulcer. Potassium sensitivity tests (PST) were performed in all cases. Eight were positive. The O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) was used as treatment outcome measures. ICSI score was from 9 to 20 (mean, 14 +/- 4) at baseline. All the patients were treated with hydrodistention initially. Efficacy was evaluated at 1 month after hydrodistention. The patients who failed to respond to the treatment and recurrence after the treatment were treated by oral or intravesical therapy.RESULTS:The 10 cases were followed up for 3 to 26 months (mean, 7.8 months) after hydrodistention. Five patients obtained symptom relief. Among them, symptom significantly relieved or disappeared in 2, with the score decreased > 7; symptom partially relieved in 3, with the score decreased > 3. Five cases failed to respond to the treatment. Two cases had recurrence 3 and 6 months after the treatment. The effective rate was 50%. The ICSI score was decreased to 11 +/- 6 at 1 month (t = 4.394, P < 0.05) after the treatment. Those who failed to respond or recurrence after hydrodistention were treated by other methods. Two case were treated with oral Pentosan Polysulfate, effective. Three cases were treated with amitriptylin, 2 effective. Three cases were treated with intravesical Dimethyl sulfoxide plus heparin plus dexamethasone, all effective.CONCLUSIONS:The diagnosis of IC should meet the symptom criteria of the NIDDK. PST has significant high positive rate in IC patient, which can be used not only for diagnosis but also for instruction. There are a lot of strategies in the management of patients with IC. Hydrodistention is the first choice.
Preparation and characterization of a novel composite acellular matrix/hyaluronic acid thermosensitive hydrogel for interstitial cystitis/bladder pain syndrome

Wei Guo,Haichao Liu,Jiaxing Zhang,Jianzhong Zhang,Fei Wang,Peng Zhang,Yunbo Yang

DOI: https://doi.org/10.1002/jbm.a.37643

Abstract:Bladder mucosa damage that causes harm to the interstitium is a recognized pathogenesis of interstitial cystitis/bladder pain syndrome (IC/BPS). The intravesical instillation of drugs is an important second-line therapy, but it is often necessary to use drugs repeatedly in the clinic because of their short residence time in the bladder cavity, which alters the therapeutic effect. To overcome this drawback, this study developed a novel composite acellular matrix/hyaluronic acid (HA) thermosensitive hydrogel (HA-Gel) using rabbit small intestinal submucosa extracellular matrix (ECM) as the thermosensitive material and HA as the drug component and examined its composition, microstructure, thermodynamic properties, temperature sensitivity, rheological properties, biocompatibility, drug release, hydrogel residue, and bacteriostatic properties. The study showed HA-Gel was liquid at temperatures of 15-37.5°C and solid at 37.5-50°C, its swelling rate decreased with increasing temperature, and its lower critical solution temperature occurred at approximately 37.5°C. This property made the hydrogel liquid at room temperature convenient for intravesical perfusion and turned into a solid about 1 min after entering the body and rising to body temperature to increase its residence time. Subsequent experiments also proved that the gel residue time of HA-Gel in vivo and the drug release time of HA in vivo could reach more than 5 days, which was significantly higher than that of HA alone, and it had good biocompatibility and antibacterial properties. Therefore, this hydrogel possesses the proper characteristics to possibly make it an ideal dosage form for IC/BPS intravesical instillation therapy.
Clinical Observation on Heat Sensitive Moxibustion Combined with Abdominal Acupuncture Therapy and Kegel Exercise in Treating 28 Females' Stress Urinary Incontinence

Dan HU,Peng DENG,Lin JIAO,Yong FU,Peng XIONG,Jianmei YE,Jun XIONG

DOI: https://doi.org/10.13288/j.11-2166/r.2017.19.011

2017-01-01

Journal of Traditional Chinese Medicine

Abstract:Objective To examine the therapeutic effect of heat sensitive moxibustion combined with abdominal acupuncture therapy and Kegel exercise in treating female stress urinary incontinence (SUI).Methods Fifty-six female patients with SUI were randomized into treatment group and control group,28 cases in each group.The control group was treated by Kegel exercise and abdominal acupuncture therapy.The treatment group was added heat sensitive moxibustion.Heat sensitive moxibustion was given twice every day (once in the morning,once in the afternoon),45 minutes to 2 hours each time,for 5 days.From the 6th day,the moxibustion was given once every day,for 25 times.Abdominal acupuncture therapy was given once every day,retaining the needle for 25min each time,for 30 days.Kegel exercise was given three times every day,15 to 30minutes each time,for 30 days.Patients' 1-hour pad test leakage volume,leakage times and total scores of International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) in both groups were examined before and after treatment.The clinical effect was evaluated.Results The total effective rate of clinical effect in the treatment group was 96.43％,while 75.00％ in the control group.The treatment group was superior to the control group (P ＜0.05).Compared before treatment,patients' 1-hour pad test leakage volume,leakage times and ICIQ-SF total scores in both groups decreased after treatment (P ＜0.01).Compared with the control group,patients' 1-hour pad test leakage volume,leakage times and ICIQ-SF total scores in the treatment group decreased (P ＜ 0.05).Conclusion Heat sensitive moxibustion combined with abdominal acupuncture therapy and Kegel exercise treating female SUI might improve female leakage symptoms of incontinence and improve their life quality.
Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

SUN Jing,YUAN Yaozong,GAO Jun,YANG Yunsheng,WU Yongdong,JI Feng,CHEN Minhu,WU Kaichun,FAN Hong

DOI: https://doi.org/10.3969/j.issn.1008-7125.2010.12.009

2010-01-01

Abstract:Background: Irritable bowel syndrome (IBS) is a commonly seen chronic functional bowel disorder that severely affects the quality of life of patients.However,the efficacy of drugs now used for treating IBS is largely unsatisfactory.Aims: To investigate the efficacy and safety of drotaverine hydrochloride for the treatment of IBS.Methods: A prospective,self-control, multicentre clinical trial was performed.Two hundred and seventeen IBS patients were enrolled and treated with oral drotaverine hydrochloride tablets 80 mg three times a day for 2 weeks.The abdominal pain,feeling of incomplete defecation,straining and urgency,as well as the stool frequency and stool form were recorded daily.Results: Compared with those before treatment,the average weekly score for abdominal pain in IBS patients was significantly decreased (0.66± 0.59 vs.1.42±0.42,P=0.0000),and the overall efficacy rate was 77.9%; the average daily stool frequency was significantly increased in IBS with constipation (IBS-C) group (0.8±0.3 vs.0.6±0.4,P=0.0004),while significantly decreased in IBS with diarrhea (IBS-D) group (1.6±0.8 vs.2.8±1.2,P=0.0000).Stool form and feeling of incomplete defecation,straining and urgency in both groups were improved in different extents.No severe adverse events were observed.Conclusions: Drotaverine hydrochloride is effective and safe in treating all subtypes of IBS.
Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis

Jung Hyun Shin,Chae-Min Ryu,Hwan Yeul Yu,Yang Soon Park,Dong-Myung Shin,Myung-Soo Choo

DOI: https://doi.org/10.1038/s41598-023-35178-5

IF: 4.6

2023-05-23

Scientific Reports

Abstract:Abstract To investigate the therapeutic effects of axitinib, a tyrosine kinase inhibitor, in an interstitial cystitis (IC) rat model. IC patients with or without Hunner lesion and non-IC controls were enrolled (n = 5/group). Bladder tissues were stained with vascular endothelial growth factor (VEGF), VEGF receptor 2 (VEGFR-2), platelet-derived growth factor (PDGF), and PDGF receptor B (PDGFR-B). The IC group showed extensive VEGFR-2 and PDGFR-B staining compared with controls. Next, ten-week-old female Sprague Dawley rats were divided into three groups (n = 10/group): sham, hydrochloride (HCl), and axitinib groups. One week after HCl instillation (day 0), the axitinib group received oral axitinib (1 mg/kg) for five consecutive days and pain was evaluated daily. Bladder function, histology and genetics were evaluated on day 7. The pain threshold significantly improved 3 days after axitinib administration. Axitinib decreased non-voiding contraction and increased the micturition interval and micturition volume and alleviated urothelial denudation, angiogenesis, mast cell infiltration, and fibrosis. HCl instillation increased the expression of tyrosine kinase receptors, including VEGFR-2 and PDGFR-B; axitinib administration inhibited their expression. Oral administration of axitinib improved pain, voiding profiles, and urothelial integrity by inhibiting angiogenesis in IC rat model. Axitinib may have potential therapeutic efficacy in IC patients.

multidisciplinary sciences
Variation and significance of histamine receptors before and after the protection to the mucous membrane of urinary bladder of interstitial cystitis rat model

Ke LIU,Hui SHAN,Yong YANG

DOI: https://doi.org/10.3760/cma.j.issn.1000-6702.2010.08.013

2010-01-01

Abstract:Objective To investigate the changes of histamine receptors in bladder before and after the treatment by sodium hyaluronate in rats of interstial cystitis (IC). Methods Twenty IC model rats were randomly divided into experimental group and control group, with 10 for each group.The bladders in experimental group were filled with sodium hyaluronate, while the rats in control group were executed at once. The bladders were dyed with HE staining, special staining and immunohistochemistry staining to count the number of mononuclear cells and mast cells and observe the changes of histamine receptors. Results In experimental group,the counts of mononuclear cells and mast cells were 12.20±2.48 and 2.90±0.87 respectively;the numbers of average optical of histamine receptor H1, H2, H3, H4 were 0.015±0.007, 0.006±0.001, 0.007±0.004, 0.061±0.026 , respectively. In control group, the counts of mononuclear cells and mast cells were 23.90±3.07 and 7.08±1.23;the numbers of average optical of histamine receptor H1, H2, H3, H4 were 0.055±0.033, 0.031±0.023, 0.033±0.017, 0.091±0.059, respectively. The differences of mononuclear cells and mast cells were significant between the 2 groups(P＜0.01). The differences of average optical of histamine receptor H1, H2, H3 between the 2 group were significant (P＜0.05), while the difference of histamine receptor H4 was not significant(P＞0.05). Conclusion Histamine receptor H1, H2, H3 take part in the development of IC, the antagons may be used for the treament of IC.
Application of Amitriptyline in the Treatment of Interstitial Cystitis

DU Peng,ZHU Xu-hui,CHEN Song,LI Tao,YAN Qiu-zhe,YANG Yong

DOI: https://doi.org/10.3321/j.issn:1000-6702.2008.07.014

2008-01-01

Abstract:Objective To evaluate the safety and efficacy of the trieyelic antidepressant amitrip tyline in the treatment of patient with interstitial cystitis (IC). Methods Fifty-four patients diagnosed with IC were recruited in this prospective three-month clinical trial. The average course of patient's history was (40. 75±11.6)months, ranging from 19-72 months. All the 54 patients received oral administration of amitriptyline for 3 months. The initial dosage of amitriptyline was 25 mg per night. After 1 week, the dosage would be increased to 50 mg if the symptom didn't relief. After another 1 week, the dosage would be increased to 75 mg if the symptoms were still exist. The patients were kept on a minimum dosage which could relief patient's IC symptoms. Clinical symptoms, such as frequency per day, maximal voiding volume and odynuria degree score, O'Leary-Sant IC symptom and problem index and quality of life score were recorded and assessed at the beginning of the study and 3 months after the treatment. Results After 3 month treatment, the pre-treatment vs post-treatment parameters of frequency per day was 28.5±8. 4 vs 15.6±3.3, odynuria degree score was 6.4± 1.5 vs 2.2±1.5 and maximal voiding volume was 108.7±62.2 ml vs 171.0±53.9 ml respectively. There was significant improvement in all the above parameters comparing between the baseline and 3 months after the treatment. At the 3 months after treatment, the pre-treatment vs post-treatment O 'Leary-Sant IC symptom and problem index and quality of life score was 26.9±4.0 vs 13.7±5.7 and 5.5±0. 5 vs 2.5±0. 6, receptively. There were significant decreases compared with the baseline. There was no serious adverse event after taking amitriptyline. Drowsiness occurred in 45 of the 54 patients at the first month administration. Of the 45 patients, 43 patients relieved and 2 patients quitted from the study. Mild weight increase was noted in 10 patients. Mild constipation was recorded in 11 patients. Mouth dryness was recorded in 9 patients. Three patients quitted because of suffering dysuria. Conclusions Oral administration of amitriptyline can effectively relieve clinical symptoms of IC and improve IC patients" quality of life. The side effects are well tolerated.
Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

William F. Rawls,Lindsey Cox,Eric S. Rovner

DOI: https://doi.org/10.1002/nau.23204

IF: 2.367

2017-02-21

Neurourology and Urodynamics

Abstract:AIMS: The purpose of this review is to update the current understanding of dimethyl sulfoxide (DMSO) and its role in the treatment of interstitial cystitis (IC).METHODS: A systematic review was conducted using the PRIMSA checklist to identify published articles involving intravesical DMSO for the treatment of IC.RESULTS: Thirteen cohort studies and three randomized-controlled trials were identified. Response rates relying on subjective measurement scores range from 61 to 95%. No increased efficacy was found with "cocktail" DMSO therapy. Great variation existed in diagnostic criteria, DMSO instillation protocols and response measurements.CONCLUSIONS: The current evidence backing DMSO is a constellation of cohort studies and a single randomized-controlled trial versus placebo. The optimal dose, dwell time, type of IC most likely to respond to DMSO, definitions of success/failure and the number of treatments are not universally agreed upon. Improvements in study design, phenotyping patients based on symptoms, as well as the emergence of reliable biomarkers of the disease may better guide the use of DMSO in the future.

urology & nephrology
The Efficacy and Safety of a Human Perirenal Adipose Tissue-Derived Stromal Vascular Fraction in an Interstitial Cystitis Rat Model

Ji Yong Ha,Eun Hye Lee,So Young Chun,Jun Nyung Lee,Yun-Sok Ha,Jae-Wook Chung,Bo Hyun Yoon,Minji Jeon,Hyun Tae Kim,Tae Gyun Kwon,Eun Sang Yoo,Bum Soo Kim

DOI: https://doi.org/10.1007/s13770-022-00505-w

2023-01-05

Tissue Engineering and Regenerative Medicine

Abstract:Interstitial cystitis (IC) is a chronic and intractable disease that can severely deteriorate patients' quality of life. Recently, stem cell therapy has been introduced as a promising alternative treatment for IC in animal models. We aimed to verify the efficacy and safety of the human perirenal adipose tissue-derived stromal vascular fraction (SVF) in an IC rat model.

engineering, biomedical,cell & tissue engineering
Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway.

Junsoo Park,Jaeho Jeong,Ji‐Youn Chun,Jisun Lim,Jinbeom Heo,W. Oh,Hwan Yeul Yu,S. Choi,M. Choo,Yonghwan Kim,Y. Cho,Miho Song,Seong Who Kim,Hyunsook Kang,Sanghyeok Park,Sung-Wuk Jang,Dong-Myung Shin

DOI: https://doi.org/10.1089/scd.2014.0459

2015-07-15

Stem Cells and Development

Abstract:Interstitial cystitis (IC) is a syndrome characterized by urinary urgency, frequency, pelvic pain, and nocturia in the absence of bacterial infection or identifiable pathology. IC is a devastating disease that certainly decreases quality of life. However, the causes of IC remain unknown and no effective treatments or cures have been developed. This study evaluated the therapeutic potency of using human umbilical cord-blood-derived mesenchymal stem cells (UCB-MSCs) to treat IC in a rat model and to investigate its responsible molecular mechanism. IC was induced in 10-week-old female Sprague-Dawley rats via the instillation of 0.1 M HCl or phosphate-buffered saline (PBS; sham). After 1 week, human UCB-MSC (IC+MSC) or PBS (IC) was directly injected into the submucosal layer of the bladder. A single injection of human UCB-MSCs significantly attenuated the irregular and decreased voiding interval in the IC group. Accordingly, denudation of the epithelium and increased inflammatory responses, mast cell infiltration, neurofilament production, and angiogenesis observed in the IC bladders were prevented in the IC+MSC group. The injected UCB-MSCs successfully engrafted to the stromal and epithelial tissues and activated Wnt signaling cascade. Interference with Wnt and epidermal growth factor receptor activity by small molecules abrogated the benefits of MSC therapy. This is the first report that provides an experimental evidence of the therapeutic effects and molecular mechanisms of MSC therapy to IC using an orthodox rat animal model. Our findings not only provide the basis for clinical trials of MSC therapy to IC but also advance our understanding of IC pathophysiology.

Medicine,Biology
Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome

Li Cui,Shuting Zou,Jing Liu,Huixia Lv,Hui Li,Zhenhai Zhang

DOI: https://doi.org/10.1016/j.intimp.2023.111404

IF: 5.714

2023-12-22

International Immunopharmacology

Abstract:Treatment strategies for constipation-predominant irritable bowel syndrome (IBS-C) continue to improve. However, effective drugs are still lacking. Herein, we explored whether sodium hyaluronate (SH) could be used to treat IBS-C. The effects of SH with different molecular weights were compared in a rat model of IBS-C. Low-molecular-weight SH (LMW-SH, 5 ∼ 10 kDa), medium-molecular-weight SH (MMW-SH, 200 ∼ 400 kDa), and high-molecular-weight SH (HMW-SH, 1300 ∼ 1500 kDa) were screened for efficacy in IBS-C using the following indicators: body weight, number of fecal pellets, fecal moisture, visceral hypersensitivity, and gastrointestinal transit rate. H-HMW-SH was the most effective in improving IBS-C symptoms. The ELISA kits indicated that H-HMW-SH reduced the levels of pro-inflammatory cytokines IL-1β, IL-18, and TNF-α in IBS-C rats. In addition, both western blot and immunofluorescence analyses showed that H-HMW-SH increased the protein expressions of claudin-1, occludin and zonula occludens-1. Furthermore, H-HMW-SH restored the balance of intestinal flora in different intestinal contents (duodenum, jejunum, ileum, and colon) and feces of rats with IBS-C. Overall, our study illustrates the therapeutic potential of H-HMW-SH in the treatment of IBS-C.

pharmacology & pharmacy,immunology
Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study

LI Ning-chen,CHEN Zhong,JIN Jie,WANG Xiao-feng,SUN Ying-hao,YE Ding-wei,ZHONG Wei-de,KONG Chui-ze,SUN Ze-yu,XIE Li-ping,WEI Qiang,YE Zhang-qun,NA Yan-qun

DOI: https://doi.org/10.3760/cma.j.issn.1000-6702.2011.01.017

2011-01-01

Abstract:Objective To verify the efficacy and safety of intravesical instillation of Cystistat in reducing complications caused by intravesical chemotherapy after TUR-BT in non-muscle invasive bladder cancer patients. Methods One hundred and twenty patients who met the inclusion/exclusion criteria were enrolled into this multi-centered, randomized and blank controlled clinical study. Selected patients were randomized into the observation group and control group. TUR-BT was carried out in both groups followed by pirarubicin (THP) and Cystistat intravesical instillation in the observation group, and THP intravesical instillation alone in control group. Visual analog scale (VAS) was used as the primary efficacy variable. The secondary efficacy variables were assessments of hematuria and bladder irritation symptoms. Adverse events, laboratory tests and changes of vital signs before and after treatment were strictly observed during observation to evaluate the efficacy and safety of Cystistat.Results Demographics and baseline characteristics were comparable in both groups. The differences and the improvement rate of VAS score in the 2 groups were significant, both P＜0.01. The changes of VAS score and the improvement rate before and after treatment were (2. 24±1.70) and (92. 92±14.76) % in observation group and (0. 70±1.82) and (20. 59±87.34)% in control group respectively. According to the covariance analysis, there were significant differences in changes of VAS score between the observation group and the control group. Also, the improvement rate of VAS score was significant from visit 2. The urine frequency decreased from 9.06±4.09 to 6. 69±2.89 in observation group and increased from 8. 85±3. 32 to 10. 15±4.40 in control group, P＜0.01. There were also significant differences in changes of nocturia before and after treatment between these two groups (P＜0.01), the nocturia decreased from 2. 88±1.74 to 1. 47±1.62 in observation group and 3. 22±2.30 to 2.91±1.73 in control group, respectively. The changes of WHO assessment for hematuria,urgency and dysuria were not significantly different between the 2 groups. No Cystistat related adverse event was observed. Conclusions Cystistat combined instillation can significantly improve the VAS score of patients with chemotherapeutic agent instillation. Relief of bladder pain, frequency and nocturia are more rapidly and more durable in Cystistat combined instillation group. The improvement is more effective in patients with a high VAS score. Cystistat instillation with chemotherapeutics agents is both well tolerated and safe.

Sodium Hyaluronate in the Treatment of Interstitial Cystitis

Intravesical Instillation of Sodium Hyaluronate for the Treatment of Refractory Non-Bacterial Cystitis:A Multicenter Study

Intravesical Hyaluronic Acid Combined with Heparin in the Treatment of Refractory Interstitial Cystitis

The efficacy and safety of amitriptyline combined with sodium hyaluronate therapy for bladder pain syndrome(Report of 58 cases)

Intravesical Hyaluronic Acid and Alkalinized Lidocaine for the Treatment of Severe Painful Bladder Syndrome/interstitial Cystitis

Intravesical Instillations of Hyaluronic Acid as First-Line Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome: Use, Efficacy and Effects on Quality of Life

Efficacy assessment of bladder hydrodistension combined with drug intravesical instilla-tion for treatment of interstitial cystitis/bladder pain syndrome

Efficacy Comparison of Interstitial Cystitis/painful Bladder Syndrome Patients Treated with Four-Drug Combination and Sodium Hyaluronate Intravesical Instillation

Intravesical Interferon Therapy for Pain Among Female Individuals With Interstitial Cystitis

[The Study of Diagnosis and Treatment of Interstitial Cystitis].

Preparation and characterization of a novel composite acellular matrix/hyaluronic acid thermosensitive hydrogel for interstitial cystitis/bladder pain syndrome

Clinical Observation on Heat Sensitive Moxibustion Combined with Abdominal Acupuncture Therapy and Kegel Exercise in Treating 28 Females' Stress Urinary Incontinence

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis

Variation and significance of histamine receptors before and after the protection to the mucous membrane of urinary bladder of interstitial cystitis rat model

Application of Amitriptyline in the Treatment of Interstitial Cystitis

Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

The Efficacy and Safety of a Human Perirenal Adipose Tissue-Derived Stromal Vascular Fraction in an Interstitial Cystitis Rat Model

Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway.

Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome

Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study